<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Urine output in arginine vasopressin disorders (diabetes insipidus)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Urine output in arginine vasopressin disorders (diabetes insipidus)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Urine output in arginine vasopressin disorders (diabetes insipidus)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel G Bichet, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Arginine vasopressin disorders (formerly, diabetes insipidus [DI]) are disorders in which polyuria due to decreased collecting tubule water reabsorption is induced by either decreased secretion of antidiuretic hormone (ADH; vasopressin deficiency, formerly called central DI) or resistance to its kidney effects (vasopressin resistance, formerly called nephrogenic DI) [<a href="#rid1">1</a>]. In most patients, the degree of polyuria is primarily determined by the degree of ADH deficiency or resistance [<a href="#rid2">2,3</a>]. Thus, the urine output may range from 2 L/day with mild partial deficiency or resistance to over 10 to 15 L/day in patients with severe disease.</p><p>Determinants of the urine output in patients with arginine vasopressin disorders will be discussed here. The causes, diagnosis, treatment of these disorders are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2289.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2313.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2382.html" rel="external">"Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DETERMINANTS OF URINE OUTPUT</span><span class="headingEndMark"> — </span>The determinants of the urine output differ between individuals with and without an arginine vasopressin disorder. The urine output in those without the disorder primarily reflects water intake, which leads to alterations in the plasma osmolality that are sensed by the osmoreceptors in the hypothalamus that regulate both antidiuretic hormone (ADH) release and thirst [<a href="#rid4">4-7</a>]. In addition to central osmoreceptors, peripheral neurons that innervate hepatic blood vessels detect osmotic shifts in portal blood and modulate ADH release, a process that is mediated partly by secretion of vasoactive intestinal peptide after water ingestion [<a href="#rid8">8</a>]. The salt and water content of gastrointestinal fluid is sensed and transmitted to the hypothalamic thirst nuclei influencing drinking behaviour [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/z/d/html/2307.html" rel="external">"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)", section on 'Regulation of plasma tonicity'</a>.)</p><p>Normally, an increase in water intake sequentially lowers the plasma osmolality, decreases ADH secretion, and reduces collecting tubule permeability to water; as a result, the excess water is rapidly excreted in a dilute urine. However, changes in water intake do not result in appropriate changes in urine output in patients with an arginine vasopressin disorder, because ADH release or effect is relatively fixed. Instead, urine output is relatively constant, regardless of water intake, unless dietary salt and/or protein intake change. Suppose, for example, that a patient has moderately severe arginine vasopressin resistance that, because of the ADH resistance, will not respond to hormone replacement. The urine osmolality in this patient cannot be raised above 150 mosmol/kg (normal maximum urine osmolality is 900 to 1200 mosmol/kg). In this setting, the excretion of solutes (primarily sodium and potassium salts and urea) is the major determinant of the urine output. If solute excretion is in the usual range (eg, 750 mosmol/kg), then the daily urine output will be 5 L/day (750 ÷ 150 = 5). In this patient, urine output will rise if solute excretion is increased and fall if solute excretion is reduced.</p><p>Thus, one way to diminish polyuria in patients with vasopressin deficiency or resistance is to restrict salt and protein intake, which in turn will reduce the solute load and solute excretion. If, for example, solute excretion fell to 525 mosmol/day, the urine output would fall to 3.5 L/day. On the other hand, the degree of polyuria can be enhanced by increasing solute excretion, as often occurs with high-protein hyperalimentation in hospitalized patients. Each gram of protein catabolized produces approximately 170 mg of urea. Thus, a protein load of 70 g (1 g/kg of body weight in a 70 kg adult) will generate approximately 11.2 g of urea nitrogen, which corresponds to approximately 400 mmol or mosm of urea. At a typical urine osmolality of 300 to 500 mosmol/kg in solute diureses, an increased urea excretion of this magnitude will require a urine output of 0.8 to 1.3 liters.</p><p>Similar considerations concerning the role of solute intake apply when ADH secretion is relatively fixed at a high level in the syndrome of inappropriate ADH secretion [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/2357.html" rel="external">"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat", section on 'High solute intake'</a>.)</p><p>Cortisol deficiency may minimize the degree of polyuria in patients with combined anterior and posterior pituitary disease [<a href="#rid11">11</a>]. Lack of cortisol, via an unknown mechanism, leads to reductions in systemic blood pressure, cardiac output, and renal blood flow [<a href="#rid12">12</a>], all of which will tend to diminish the urine output. Lack of cortisol also may increase ADH release in patients with partial vasopressin deficiency (see  <a class="medical medical_review" href="/z/d/html/2314.html" rel="external">"Hyponatremia and hyperkalemia in adrenal insufficiency"</a>). Reversal of these effects via the administration of cortisol will unmask the vasopressin deficiency, resulting in the rapid onset of polyuria [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Development of hyperglycemia and glucosuria</span><span class="headingEndMark"> — </span>The polyuria in arginine vasopressin disorders is typically matched by an equivalent increase in water intake via stimulation of thirst. Some patients cannot take fluids orally and are treated with large volumes of intravenous fluid replacement, usually with dextrose and water solutions. This regimen can induce marked hyperglycemia due to the delivery of glucose at a rate that exceeds endogenous metabolic capacity for glucose even in nondiabetics [<a href="#rid13">13</a>]. The associated glucosuria, acting as an osmotic diuretic, can lead to a clinically confusing increase in the urine output that is now <strong>ADH resistant</strong>. In this setting, however, the urine osmolality is typically above 300 mosmol/kg (if ADH has been given) with the polyuria being driven by the solute load. The administration of insulin to correct the hyperglycemia will restore ADH sensitivity. Glucosuria from <a class="drug drug_general" data-topicid="96484" href="/z/d/drug information/96484.html" rel="external">empagliflozin</a>, a sodium glucose cotransporter 2 inhibitor, has been used successfully to increase osmotic diuresis and improved plasma sodium in patients with SIADH [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria", section on 'Solute (osmotic) diuresis'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>The polyuria in incomplete arginine vasopressin deficiency (ie, partial deficiency of antidiuretic hormone [ADH]) is typically exacerbated by pregnancy. The placenta releases vasopressinases that enhance the catabolism of ADH. This is of no clinical importance in healthy females but can lead to polyuria when secretory reserve is diminished due to underlying vasopressin deficiency. Treatment is most effective with the analog, <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a>, which is resistant to the vasopressinases. (See  <a class="medical medical_review" href="/z/d/html/404.html" rel="external">"Maternal adaptations to pregnancy: Renal and urinary tract physiology"</a>.)</p><p class="headingAnchor" id="H233814"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Arginine vasopressin disorders are those in which polyuria due to decreased collecting tubule water reabsorption is induced by either decreased secretion of antidiuretic hormone (ADH; vasopressin deficiency, formerly central DI) or resistance to its kidney effects (vasopressin resistance, formerly nephrogenic DI). In most patients, the degree of polyuria is primarily determined by the degree of ADH deficiency or resistance. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with arginine vasopressin disorders, urine output is relatively constant, regardless of water intake, unless dietary salt and/or protein intake change. Urine output will rise if solute excretion is increased and fall if solute excretion is reduced. Thus, one way to diminish polyuria in patients with arginine vasopressin disorders is to restrict salt and protein intake, which in turn will reduce the solute load and solute excretion. (See <a class="local">'Determinants of urine output'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If patients with arginine vasopressin disorders are treated with large volumes of intravenous fluid replacement, usually with dextrose and water solutions, the delivery of glucose may exceed endogenous metabolic capacity, and the associated glucosuria, acting as an osmotic diuretic, can lead to a clinically confusing increase in the urine output that is resistant to ADH. (See <a class="local">'Development of hyperglycemia and glucosuria'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bockenhauer D, Knoers NVAM, Bichet DG. What's in a name? That which we call diabetes does not taste sweet! Pediatr Nephrol 2023; 38:937.</a></li><li class="breakAll">Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.758.</li><li><a class="nounderline abstract_t">Christ-Crain M, Bichet DG, Fenske WK, et al. Diabetes insipidus. Nat Rev Dis Primers 2019; 5:54.</a></li><li><a class="nounderline abstract_t">Zaelzer C, Hua P, Prager-Khoutorsky M, et al. ΔN-TRPV1: A Molecular Co-detector of Body Temperature and Osmotic Stress. Cell Rep 2015; 13:23.</a></li><li><a class="nounderline abstract_t">Oka Y, Ye M, Zuker CS. Thirst driving and suppressing signals encoded by distinct neural populations in the brain. Nature 2015; 520:349.</a></li><li><a class="nounderline abstract_t">Zimmerman CA, Leib DE, Knight ZA. Neural circuits underlying thirst and fluid homeostasis. Nat Rev Neurosci 2017; 18:459.</a></li><li><a class="nounderline abstract_t">Bichet DG. Regulation of Thirst and Vasopressin Release. Annu Rev Physiol 2019; 81:359.</a></li><li><a class="nounderline abstract_t">Ichiki T, Wang T, Kennedy A, et al. Sensory representation and detection mechanisms of gut osmolality change. Nature 2022; 602:468.</a></li><li><a class="nounderline abstract_t">Zimmerman CA, Huey EL, Ahn JS, et al. A gut-to-brain signal of fluid osmolarity controls thirst satiation. Nature 2019; 568:98.</a></li><li><a class="nounderline abstract_t">Decaux G. Variations in daily urine solute output in patients with NDI, CDI, SIADH, and NSIAD: Clinical implications. Clin Nephrol 2021; 96:233.</a></li><li><a class="nounderline abstract_t">Martin MM. Coexisting anterior pituitary and neurohypophyseal insufficiency. A syndrome with diagnostic implication. Arch Intern Med 1969; 123:409.</a></li><li><a class="nounderline abstract_t">Linas SL, Berl T, Robertson GL, et al. Role of vasopressin in the impaired water excretion of glucocorticoid deficiency. Kidney Int 1980; 18:58.</a></li><li><a class="nounderline abstract_t">Freidenberg GR, Kosnik EJ, Sotos JF. Hyperglycemic coma after suprasellar surgery. N Engl J Med 1980; 303:863.</a></li><li><a class="nounderline abstract_t">Refardt J, Imber C, Sailer CO, et al. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis. J Am Soc Nephrol 2020; 31:615.</a></li></ol></div><div id="topicVersionRevision">Topic 2372 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36369299" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : What's in a name? That which we call diabetes does not taste sweet!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36369299" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : What's in a name? That which we call diabetes does not taste sweet!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31395885" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26387947" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : ΔN-TRPV1: A Molecular Co-detector of Body Temperature and Osmotic Stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25624099" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Thirst driving and suppressing signals encoded by distinct neural populations in the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28638120" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Neural circuits underlying thirst and fluid homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30742785" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Regulation of Thirst and Vasopressin Release.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35082448" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Sensory representation and detection mechanisms of gut osmolality change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30918408" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A gut-to-brain signal of fluid osmolarity controls thirst satiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34236307" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Variations in daily urine solute output in patients with NDI, CDI, SIADH, and NSIAD: Clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4182323" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Coexisting anterior pituitary and neurohypophyseal insufficiency. A syndrome with diagnostic implication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7218660" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Role of vasopressin in the impaired water excretion of glucocorticoid deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7412803" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hyperglycemic coma after suprasellar surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32019783" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
